ArticleKidney cancer journal : official journal of the Kidney Cancer Association2024
Kidney function decline in cT1a patients treated with Microwave Ablation versus Partial Nephrectomy.
Article in Kidney cancer journal : official journal of the Kidney Cancer Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: Microwave ablation (MWA) is an emerging treatment modality for clinical T1a (cT1a) small renal masses (SRM) with studies showing it has comparable oncological outcomes to partial nephrectomy (PN). However, more research is needed to the impact of each treatment on kidney function decline. Objective: To compare the progression of kidney function decline in patients with cT1a SRM treated with MWA or PN. Methods: This study included prospective data on patients treated between 2015-2021 with kidney function data collected from 2015-2024 from a single institutional database. Three outcomes for kidney function decline were examined: 30% decline in estimated glomerular filtration rate (eGFR) compared to pre-treatment, chronic kidney disease (CKD) upstaging compared to pre-treatment and eGFR <60 mL/min/1.73m Results: Among 97 MWA and 49 PN included, MWA patients were older, had lower baseline eGFR, and higher rates of CKD prior to treatment. Univariate Cox proportional hazard model showed treatment modality was not significantly associated with reaching kidney decline endpoints. After adjusting for patient characteristics (age, race, baseline eGFR, Charlson Comorbidity Index), only baseline eGFR was associated with reaching kidney function endpoints. Conclusion: There was no statistically significant difference in kidney function decline between PN and MWA treatments for cT1a SRM. After adjusting for patient factors, the higher hazard for MWA was attenuated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.